Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the tariff over the ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...

Digital physical therapy company Hinge Health went public last week, raising $437 million and ending an IPO drought for ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.

Our writer takes a look at three red-hot growth stocks that have more than doubled this year to see if any of them interest ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL ...

Keynotes from Bayer, Lonza, MSD, Novo Nordisk, Recipharm, and Teva will showcase how connected platforms and AI can streamline the development of new medicines ...